PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces another positive test result. The result shows that CypCap material does not cause systemic toxicity.

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner,

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Löhr to PharmaCyte's Board of Directors. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, stated, “PharmaCyte is extremely pleased that Dr. Löhr has joined our Board of Directors. There is no one who could be mo

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech successfully completed a 24-month stability study of its clinical trial product candidate.

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech reports positive third quarter results and operational highlights.

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte announces genetic stability of the cytochrome P450 gene and site of integration for its pancreatic cancer product candidate.

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA.

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

PharmaCyte has developed a cell encapsulation technique that allows foreign cells to be injected into the body without triggering an immune response. The company is using their encapsulation technique as a basis for developing treatments for diabetes and cancer.

Is This A Good Time To Invest In PharmaCyte?

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech Chief Executive Officer to present at the H.C. Wainwright BioConnect Conference.

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech biocompatibility study proves that its capsule material is not toxic for the encapsulated cells inside the capsules.

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte has successfully completed a 36 month stability study on its Master Cell Bank cells that will be used for treatment of pancreatic cancer.

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech reports on its second quarter financial results and its operational highlights.

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech successfully complete the cytochrome P450 site of integration DNA sequencing assay required by the FDA to lift the clinical hold.

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech launches its malignant ascites program with commencement of a pivotal preclinical study.

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces that its clinical trial product material does not cause skin irritation passing another biocompatibility test.

PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

Mind Medicine MindMed

Sesen Bio Inc.

Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.

3 Penny Stocks Waiting on FDA Approval for Rocket Fuel

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces that its encapsulation material does not alter cellular DNA.

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech releases more positive results from the FDA required biocompatibility tests. The clinical trial capsules passed the tests.

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of its CypCaps trial product candidate. These results were from an "In Vitro Complement Activation Study of Empty Cellulose Sulphate Capsules," the same capsules PharmaCyte uses in its treatment for pancreatic cancer.

Why Are PharmaCyte Shares Moving Higher On Thursday?

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces positive results of one of the biocompatibility studies required by the FDA.

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

Atossa Genetics

Clovis Oncology

VBI Vaccines

vTv Therapeutics

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace.

7 Penny Stocks Waiting on The FDA for Rocket Fuel

The stock price of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is trading at over 20% pre-market today. This is why it happened.

PMCB Stock: Why It Is Trading Higher Today

There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.

After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble

The stock price of PharmaCyte Biotech Inc (NASDAQ: PMCB) is trading higher during premarket today.  Investors are expecting a major announcement from the company today.

News for PharmaCyte Biotech Stock (PMCB)